• European organizations update soft tissue and visceral sarcomas guideline

    Olaratumab is no longer recommended as first-line treatment.

  • Olaratumab withdrawn from EU market due to lack of efficacy

    Consider alternative treatment options to olaratumab since available stock will expire by April 2020.

  • Cancer: study shows increasing use of weed, but not opioids

    Can legalization help counteract the opioid crisis?

  • ECCMID 2019 - Cancer chemotherapy drives antimicrobial resistance by disrupting the gut microbiome

    By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.

  • EU cancer deaths projected to continue declining in 2019

    Reductions in mortality driven by lung cancer in men, breast cancer in women.

  • ASCO-SITC 2019—NKTR-262 + bempegaldesleukin does well in solid-tumor REVEAL

    Data from the ongoing dose-escalation stage of a first-in-human phase 1/2 clinical study.

  • Use of CRISPR-Cas9 gene editing technique to reduce Kaposi’s sarcoma-associated herpesvirus latency

    CRISPR-Cas9 has been used for the first time to successfully edit the latency-associated nuclear antigen (LANA) of the KSHV virus, and reduce viral episome burden in infected cells

  • Early and continuous HIV treatment offers protection against a large number of AIDS and non-AIDS related events

    A pooled analysis of data from SMART and START studies allows calculating the magnitude and quality of benefits of life-long antiretroviral treatment

  • FDA approves Vitrakvi for solid tumors driven by rare mutation

    "Site-agnostic" oral therapy for tumors with NTRK gene fusion.

  • ESMO 2018 – French study exposes barriers to the inclusion of 12 to 25-year-olds in both adult and paediatric phase 1 and 2 clinical trials

    A more flexible and tailored approach to trial recruitment could help 12 to 25-year-old patients by giving them access to new cancer treatments.

  • ESMO 2018 – Reduced mortality, relapses for sarcoma patients in French reference centre

    The establishment of a national reference centre in France with multidisciplinary committees (RCP) has markedly improved outcomes for sarcoma patients.

  • Cancer patients trust nontraditional therapies, unaware of risks

    Oncologists should replace the Internet as a primary source of information.

  • Sarcoma: 29% of major drug interactions involve alternative medicine

    Drug interactions more common with TKIs than chemotherapy.

  • aBC or mBC: FDA expands approval of ribociclib under new, faster oncology pilot review process

    The new review process will streamline FDA evaluation of other oncology drugs.

  • HIV: long-term viral suppression attenuates cancer risk

    Early ART initiation, adherence, and screening are keys to HIV cancer risk reduction.

  • New projections show substantial increases in prostate, lung cancer rates in HIV adults

    Aging patients with HIV require more comprehensive prostate, lung cancer screening.

  • Cochrane: inadequate evidence to guide antidepressant use in cancer

    Available studies were very few and of low quality.

  • Load more